Neil Stahl Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Neil Stahl is EVP Research and Development of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 49,599 shares of REGN, which is worth approximately $36.9 Million. The most recent transaction as insider was on Aug 13, 2024, when has been sold 500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.6K

0% 3M change

5.88% 12M change

Total Value Held $36.9 Million

NEIL STAHL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 13 2024	SELL Bona fide gift	-	500 Reduced 1.0%	49,599 Common Stock
Aug 12 2024	SELL Bona fide gift	-	900 Reduced 1.76%	50,099 Common Stock
Aug 08 2024	SELL Open market or private sale	$5,633,599 $1084.01 p/Share	5,197 Reduced 9.25%	50,999 Common Stock
Aug 02 2024	SELL Payment of exercise price or tax liability	$20,165,049 $1093.49 p/Share	18,441 Reduced 24.71%	56,196 Common Stock
Aug 02 2024	BUY Exercise of conversion of derivative security	$13,134,927 $555.67 p/Share	23,638 Added 24.05%	74,637 Common Stock
Feb 26 2024	SELL Bona fide gift	-	1,020 Reduced 1.96%	50,999 Common Stock
Feb 07 2024	SELL Open market or private sale	$7,638,445 $950.41 p/Share	8,037 Reduced 13.38%	52,019 Common Stock
Feb 02 2024	SELL Payment of exercise price or tax liability	$21,728,391 $956.65 p/Share	22,713 Reduced 27.44%	60,056 Common Stock
Feb 02 2024	BUY Exercise of conversion of derivative security	$12,289,545 $399.66 p/Share	30,750 Added 27.09%	82,769 Common Stock
Dec 11 2023	SELL Payment of exercise price or tax liability	$611,965 $844.09 p/Share	725 Reduced 1.37%	52,019 Common Stock
Dec 08 2023	SELL Payment of exercise price or tax liability	$682,626 $843.79 p/Share	809 Reduced 1.54%	51,891 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	853 Added 1.59%	52,744 Common Stock
Nov 10 2023	SELL Bona fide gift	-	400 Reduced 0.75%	52,700 Common Stock
Aug 22 2023	SELL Open market or private sale	$9,814,581 $841.37 p/Share	11,665 Reduced 18.01%	53,100 Common Stock
Aug 21 2023	SELL Payment of exercise price or tax liability	$31,948,005 $833.39 p/Share	38,335 Reduced 37.18%	64,765 Common Stock
Aug 21 2023	BUY Exercise of conversion of derivative security	$19,983,000 $399.66 p/Share	50,000 Added 32.66%	103,100 Common Stock
Dec 16 2022	BUY Grant, award, or other acquisition	-	1,101 Added 2.03%	53,100 Common Stock
Dec 09 2022	SELL Payment of exercise price or tax liability	$351,028 $753.28 p/Share	466 Reduced 0.89%	51,999 Common Stock
Nov 08 2022	SELL Bona fide gift	-	330 Reduced 0.63%	52,465 Common Stock
Aug 05 2022	SELL Open market or private sale	$14,600,959 $613.95 p/Share	23,782 Reduced 31.06%	52,795 Common Stock
Aug 04 2022	SELL Payment of exercise price or tax liability	$43,656,634 $613.0 p/Share	71,218 Reduced 48.19%	76,577 Common Stock
Aug 04 2022	BUY Exercise of conversion of derivative security	$25,690,849 $270.43 p/Share	95,000 Added 39.13%	147,795 Common Stock
Feb 18 2022	SELL Bona fide gift	-	335 Reduced 0.63%	52,795 Common Stock
Dec 11 2021	SELL Payment of exercise price or tax liability	$500,248 $664.34 p/Share	753 Reduced 1.4%	53,130 Common Stock
Dec 08 2021	BUY Grant, award, or other acquisition	-	2,926 Added 5.15%	53,883 Common Stock

Neil Stahl

EVP Research and Development

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account